Deidré Prince1, Daniel Rossouw2, Claudia Davids2, Sietske Rubow3. 1. Radionuclide Production Department, iThemba LABS, PO Box 722, Somerset West, 7129, South Africa. deidre@tlabs.ac.za. 2. Radionuclide Production Department, iThemba LABS, PO Box 722, Somerset West, 7129, South Africa. 3. Nuclear Medicine Division, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town, 8000, South Africa.
Abstract
PURPOSE: This study was aimed to develop single vial 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptide kits to be used with fractionated eluates from a SnO2-based 68Ge/68Ga generator. PROCEDURES: Kits were formulated with 35 μg DOTA-Tyr3-Thre8-octreotide, DOTA-[Tyr3]-octreotide and DOTA-[NaI3]-octreotide (DOTATATE, DOTATOC and DOTANOC) and sodium acetate powder, vacuum-dried and stored at -20 °C for up to 12 months. Labelling of the kits was carried out with 2 ml 68Ga eluate. Comparative labelling was carried out using aqueous DOTA-peptide stock solutions kept frozen at -20 °C for up to 12 months. RESULTS: The quality of the kits was found to be suitable over a 1-year storage period (pH, sterility, endotoxin content, radiolabelling efficiency and radiochemical yields of 68Ga-labelled DOTA-peptides). Radiochemical yields ranged from 73 to 83 %, while those obtained from stock solutions from 64 to 79 %. No significant decline in kit labelling yields was observed over a 12-month storage period. CONCLUSION: The single vial kit formulations met the quality release specifications for human administration and appear to be highly advantageous over using peptide stock solutions in terms of stability and user-friendliness.
PURPOSE: This study was aimed to develop single vial 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptide kits to be used with fractionated eluates from a SnO2-based 68Ge/68Ga generator. PROCEDURES: Kits were formulated with 35 μg DOTA-Tyr3-Thre8-octreotide, DOTA-[Tyr3]-octreotide and DOTA-[NaI3]-octreotide (DOTATATE, DOTATOC and DOTANOC) and sodium acetate powder, vacuum-dried and stored at -20 °C for up to 12 months. Labelling of the kits was carried out with 2 ml 68Ga eluate. Comparative labelling was carried out using aqueous DOTA-peptide stock solutions kept frozen at -20 °C for up to 12 months. RESULTS: The quality of the kits was found to be suitable over a 1-year storage period (pH, sterility, endotoxin content, radiolabelling efficiency and radiochemical yields of 68Ga-labelled DOTA-peptides). Radiochemical yields ranged from 73 to 83 %, while those obtained from stock solutions from 64 to 79 %. No significant decline in kit labelling yields was observed over a 12-month storage period. CONCLUSION: The single vial kit formulations met the quality release specifications for human administration and appear to be highly advantageous over using peptide stock solutions in terms of stability and user-friendliness.
Authors: Wouter A P Breeman; Marion de Jong; Erik de Blois; Bert F Bernard; Mark Konijnenberg; Eric P Krenning Journal: Eur J Nucl Med Mol Imaging Date: 2005-01-18 Impact factor: 9.236
Authors: Erik de Blois; Ho Sze Chan; Clive Naidoo; Deidre Prince; Eric P Krenning; Wouter A P Breeman Journal: Appl Radiat Isot Date: 2010-11-23 Impact factor: 1.513
Authors: Konstantin P Zhernosekov; Dimitry V Filosofov; Richard P Baum; Peter Aschoff; Heiner Bihl; Anatoli A Razbash; Markus Jahn; Mark Jennewein; Frank Rösch Journal: J Nucl Med Date: 2007-09-14 Impact factor: 10.057
Authors: Clemens Decristoforo; Roger Knopp; Elisabeth von Guggenberg; Marco Rupprich; Thorsten Dreger; Andre Hess; Irene Virgolini; Roland Haubner Journal: Nucl Med Commun Date: 2007-11 Impact factor: 1.690
Authors: Ferdinand Sudbrock; Thomas Fischer; Beate Zimmermanns; Mehrab Guliyev; Markus Dietlein; Alexander Drzezga; Klaus Schomäcker Journal: EJNMMI Res Date: 2014-07-24 Impact factor: 3.138
Authors: Ruslan Cusnir; Andrew Cakebread; Margaret S Cooper; Jennifer D Young; Philip J Blower; Michelle T Ma Journal: RSC Adv Date: 2019-11-14 Impact factor: 4.036